BTCY vs. MBOT, NMTC, SURG, POCI, XAIR, COCH, VVOS, IRIX, FEMY, and CODX
Should you be buying Biotricity stock or one of its competitors? The main competitors of Biotricity include Microbot Medical (MBOT), NeuroOne Medical Technologies (NMTC), SurgePays (SURG), Precision Optics (POCI), Beyond Air (XAIR), Envoy Medical (COCH), Vivos Therapeutics (VVOS), IRIDEX (IRIX), Femasys (FEMY), and Co-Diagnostics (CODX). These companies are all part of the "medical equipment" industry.
Biotricity vs.
Microbot Medical (NASDAQ:MBOT) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking.
Microbot Medical has a net margin of 0.00% compared to Biotricity's net margin of -97.05%. Biotricity's return on equity of 0.00% beat Microbot Medical's return on equity.
Microbot Medical has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
In the previous week, Microbot Medical had 2 more articles in the media than Biotricity. MarketBeat recorded 3 mentions for Microbot Medical and 1 mentions for Biotricity. Microbot Medical's average media sentiment score of 0.02 beat Biotricity's score of 0.00 indicating that Microbot Medical is being referred to more favorably in the media.
16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 10.5% of Microbot Medical shares are owned by company insiders. Comparatively, 10.1% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Microbot Medical received 347 more outperform votes than Biotricity when rated by MarketBeat users. Likewise, 70.67% of users gave Microbot Medical an outperform vote while only 0.00% of users gave Biotricity an outperform vote.
Microbot Medical has higher earnings, but lower revenue than Biotricity. Microbot Medical is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.
Microbot Medical presently has a consensus price target of $7.00, suggesting a potential upside of 295.48%. Given Microbot Medical's stronger consensus rating and higher probable upside, research analysts plainly believe Microbot Medical is more favorable than Biotricity.
Summary
Microbot Medical beats Biotricity on 14 of the 17 factors compared between the two stocks.
Get Biotricity News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biotricity Competitors List
Related Companies and Tools
This page (NASDAQ:BTCY) was last updated on 1/21/2025 by MarketBeat.com Staff
Free BTCY Stock Alerts